BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//talks.cam.ac.uk//v3//EN
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:19700329T010000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:19701025T020000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
CATEGORIES:Science@Darwin
SUMMARY:Inhibition of EGF receptor signalling: The Discove
 ry of AZD9291 - Ray Finlay\, Darren Cross &amp\; R
 ichard A Ward
DTSTART;TZID=Europe/London:20150226T163000
DTEND;TZID=Europe/London:20150226T180000
UID:TALK57905AThttp://talks.cam.ac.uk
URL:http://talks.cam.ac.uk/talk/index/57905
DESCRIPTION:Small molecule inhibitors of the Epidermal Growth 
 Factor Receptor (EGFR) tyrosine kinase such as gef
 itinib and erlotinib have been employed successful
 ly in the treatment of non-small cell lung cancer 
 (NSCLC) patients harboring an activating/sensitisi
 ng mutation in EGFR (“single mutant”\, EGFRm +). H
 owever\, these drugs are not curative and most pat
 ients will progress due to acquired resistance\, w
 ith up to two thirds of these patients progressing
  due to acquisition of a second EGFR T790M mutatio
 n. This presentation will describe the background 
 disease biology\, and some key aspects of the pre-
 clinical bioscience and medicinal chemistry progra
 ms that led to the discovery of AZD9291\, an orall
 y bioavailable\, irreversible EGFR inhibitor of bo
 th the resistance and sensitising mutations that a
 lso spares the wild type form of the receptor\, in
 hibition of which is believed to drive the observe
 d dose limiting toxicities (such as skin rash and 
 diarrhea) for these first generation therapies in 
 the clinic.\n\nFirst dose in man was achieved with
  AZD9291 in March 2013 and clinical findings to da
 te have been very exciting\, and some current clin
 ical data will also be shared.\n\nRegistration nec
 essary: https://www.eventbrite.co.uk/event/1559985
 9600
LOCATION:Building 310 on the Cambridge Science Park
CONTACT:Claus Bendtsen
END:VEVENT
END:VCALENDAR